Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of TAK-648 in Healthy Participants
NCT02480439Phase 1Completed
- Sponsor
- Takeda
- Start
- Jun 2015
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of TAK-648 in type 2 diabetes mellitus (T2DM) and diabetic nephropathy (DN) (3 arms), sponsored by Takeda. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-Time Curve From Time 0 to Last Quantifiable Concentration and 1 more. Started Jun 2015; status: completed.
02
Drugs
TAK-648
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT02480439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02480439.